Siri Greeley
Section of Endocrinology, Diabetes and Metabolism
Assistant Professor of Medicine

Training

DegreeYearInstitutionArea
PhD2002University of PennsylvaniaImmunology
MD2003University of Pennsylvania 
Residency2006The University of ChicagoPediatrics
Fellowship2009The University of ChicagoPediatric Endocrinology

Academic Interests

Dr. Greeley's research and clinical focus is on patients with neonatal diabetes (NDM). He has established the national Neonatal Diabetes Registry, which now includes over one hundred probands with diabetes under a year of age. About 50% of those diagnosed under 6 months carry a mutation in either subunit of the KATP channel and can be treated with oral sulfonylureas in lieu of insulin. Dr. Greeley facilitates this transition in patients who subsequently have had a dramatic improvement in metabolic control and quality of life. Dr. Greeley participates in the search for new diabetes genes through probands with NDM and no known genetic cause. As part of a multifaceted investigation, Dr. Greeley recently started a study of certain patient groups in whom beta cell function may be improved by various treatments. Further, he is collaborating with Michael Msall, Chief of Developmental Pediatrics to develop a screening methodology for identification of those with neurodevelopmental and behavioral disabilities and with Eve Van Cauter and Leila Gozal to study the complex interplay between metabolic dysregulation and sleep in our patient population.


Clinical Interests

Childhood diabetes and endocrine disorders


Representative Publications

  1. Sulfonylurea Treatment Before Genetic Testing in Neonatal Diabetes: Pros and Cons. Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, Zimmer CA, Davis AO, Kotlyarevska K, Naylor RN, Philipson LH, Greeley SA. J Clin Endocrinol Metab. 2014 Sep 19:jc20142494. [Epub ahead of print] PMID: 25238204
  2. Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder. Shalev SA, Tenenbaum-Rakover Y, Horovitz Y, Paz VP, Ye H, Carmody D, Highland HM, Boerwinkle E, Hanis CL, Muzny DM, Gibbs RA, Bell GI, Philipson LH, Greeley SA. Pediatr Diabetes. 2014 May;15(3):252-6. doi: 10.1111/pedi.12086. Epub 2013 Oct 21. PMID: 24138066
  3. Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas. Shah RP, Spruyt K, Kragie BC, Greeley SA, Msall ME. Diabetes Care. 2012 Oct;35(10):2086-8. Epub 2012 Aug 1. PMID: 22855734
  4. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Greeley SA, Naylor RN, Philipson LH, Bell GI. Curr Diab Rep. 2011 Dec;11(6):519-32. doi: 10.1007/s11892-011-0234-7. Review.PMID: 21993633
  5. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Greeley SA, John PM, Winn AN, Ornelas J, Lipton RB, Philipson LH, Bell GI, Huang ES. Diabetes Care. 2011 Mar;34(3):622-7. doi: 10.2337/dc10-1616. Epub 2011 Jan 27.PMID: 21273495



More Information

For more information about Dr. Siri Greeley publications and research collaborations , please click here